DUSP3 / VHR Protein

Sino Biological Inc. liefert DUSP3 / VHR Protein mit höherer Qualität und günstiger Kosten im Vergleich mit anderen globalen Lieferanten.

Weitere Informationen über DUSP3 / VHR Protein lesen Sie bitte: http://www.sinobiological.com/DUSP3-VHR-Protein-a-2363.html

Produkt-Information von DUSP3 / VHR Protein

QC Testing von DUSP3 / VHR Protein

Purity:	> 95 % as determined by SDS-PAGE	SDS-PAGE: DUSP3 protein
Endotoxin:	< 1.0 EU per μg of the protein as determined by the LAL method
Stability:	Samples are stable for up to twelve months from date of receipt at -70℃
Predicted N terminal:	Gly
Molecular Mass:	The secreted recombinant human VHR consists of 187 amino acids and predicts a molecular mass of 20.6 KDa. The apparent molecular mass of the protein is approximately 21 KDa in SDS-PAGE under reducing conditions due to glycosylation.
Formulation:	Lyophilized from sterile 20mM Tris, 500mM NaCl, 10% glycerol, pH 8.0. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.

Usage Guide von DUSP3 / VHR Protein

Verwandte Produkt-Information von DUSP3 / VHR Protein

Beschreibung von DUSP3 / VHR Protein

Vaccinia H1-related phosphatase ( VHR ), also known as Dual Specificity Phosphatase 3 ( DUSP3 ), is a member of the dual specificity protein phosphatase subfamily. DUSPs are a heterogeneous group of protein phosphatases that can dephosphorylate both phosphotyrosine and phosphoserine/phosphothreonine residues within the one substrate. DUSPs have been implicated as major modulators of critical signalling pathways that are dysregulated in various diseases. DUSP3/VHR is an endogenous inhibitor of several MAPKs, including c-Jun N-terminal kinase. Unlike typical DUSPs, VHR lacks mitogen-activated protein kinase (MAPK)-binding domain, and shows poor activity against MAPKs. VHR is required for cell-cycle progression as it modulates MAP kinase activation in a cell-cycle phase-dependent manner. Thus, it plays a critical role in cell cycle progression and is itself regulated during the cell cycle. VHR can be considered as a new marker for cancer progression in cervix carcinoma and potential new target for anticancer therapy.

References

1. Todd JL. et al., 1999, J Biol Chem. 274: 13271-80.
2. Patterson KI. et al., 2009, Biochem J. 418 (3): 475-89.
3. Hao L. et al., 2007, Int J Cancer. 121 (1): 39-46.
4. Cerignoli F. et al., 2006, Cell Cycle. 5 (19): 2210-5.
5. Henkens R. et al., 2008, BMC Cancer. 8: 147.